Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 4;13(1):281.
doi: 10.3390/jcm13010281.

Trends of Diagnosis, Disease Course, and Treatment of Atopic Dermatitis 2012-2021: Real-World Data from a Large Healthcare Provider

Clara Weil  1 , Roni Adiri  2 , Gabriel Chodick  1   3 , Merril Gersten  2 , Eran Cohen Barak  4   5
Affiliations

Trends of Diagnosis, Disease Course, and Treatment of Atopic Dermatitis 2012-2021: Real-World Data from a Large Healthcare Provider

Clara Weil et al. J Clin Med. .

Abstract

In the last decade, new treatments for atopic dermatitis (AD) have emerged. We aimed to describe trends of the diagnosis, disease course, and treatment of AD over a decade (2012-2021) using data from Maccabi Healthcare Services (a 2.7-million-member healthcare provider in Israel). The AD prevalence was stable (4.0% on 31 December 2021 vs. 4.3% on 31 December 2012). The annual AD incidence was also stable (5.8/1000 in 2012 and 5.7/1000 in 2021). AD-related treatment use was highest in the first year post-diagnosis, and it included, among children (n = 87,414) vs. adults (n = 36,865), low-potency topical corticosteroids (TCS) (41.8% vs. 27.1%), mid-potency TCS (30.1% vs. 28.1%), high-potency TCS (34.9% vs. 60.3%), topical calcineurin inhibitor (10.8% vs. 10.1%), phosphodiesterase-4-inhibitor (0.3% vs. 0.7% overall; approved in 2019), phototherapy (0.1% vs. 2.3%), and systemic/biologic treatments (13.0% vs. 13.3%). Among children diagnosed in 2012 and followed through to 2021 (n = 5248), 21.5% had ≥1 AD diagnosis/treatment 10 years later (among 3223 adults: 38.3%). We conclude that the incidence and prevalence rates of AD were comparable to those in similar database studies and remained relatively stable over the past decade. The results underscore the burden of medication use among children and adults, particularly in the first year after AD diagnosis, and the low rate of AD diagnosis among patients originally diagnosed as children 10 years earlier.

Keywords: atopic dermatitis; incidence; real-world data.

PubMed Disclaimer

Conflict of interest statement

RA reports being an employee of Pfizer. MG reports owning Pfizer stock and is employed by Pfizer. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Age- and sex-specific prevalence of AD (31 December 2021).
Figure 2
Figure 2
Age-specific annual incidence of AD (2012–2021): (A) by calendar year; (B) Overall and by sex (average during the study period).
Figure 3
Figure 3
Dispensed AD-related medication over time, relative to AD diagnosis, by age at AD diagnosis. Note: treatment defined as at least 1 dispensed prescription per year. The denominator included all patients enrolled at the mid-point of a given year.
See this image and copyright information in PMC

References

    1. Laughter M., Maymone M.B., Mashayekhi S., Arents B.W., Karimkhani C., Langan S., Dellavalle R., Flohr C. The global burden of atopic dermatitis: Lessons from the Global Burden of Disease Study 1990–2017. Br. J. Dermatol. 2021;184:304–309. doi: 10.1111/bjd.19580. - DOI - PubMed
    1. Israel Central Bureau of Statistics Characterization and Classification of Geographic Units by the Socio-Economic Level of the Population 2015. Publication No. 1765. [(accessed on 1 October 2021)]; Available online: https://www.cbs.gov.il/he/publications/DocLib/2019/1765_socio_economic_2....
    1. Rossman H., Shilo S., Meir T., Gorfine M., Shalit U., Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat. Med. 2021;27:1055–1061. doi: 10.1038/s41591-021-01337-2. - DOI - PubMed
    1. Chodick G., Heymann A.D., Shalev V., Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur. J. Epidemiol. 2003;18:1143–1146. doi: 10.1023/B:EJEP.0000006635.36802.c8. - DOI - PubMed
    1. Shalev V., Chodick G., Goren I., Silber H., Kokia E., Heymann A.D. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int. J. Cardiol. 2011;152:345–349. doi: 10.1016/j.ijcard.2010.08.002. - DOI - PubMed

LinkOut - more resources